Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Significant Growth in Short Interest

Key Points

• Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) experienced a significant 37.2% increase in short interest in July, rising to 76,300 shares from 55,600 shares.
• Wall Street analysts have upgraded Coeptis Therapeutics from a "sell" rating to a "hold" rating, indicating a potentially positive sentiment for the company's future performance.
• The company's stock opened at $13.57, with a market capitalization of $47.63 million and a one-year price range between $2.31 and $14.70.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 76,300 shares, anincreaseof37.2% from the July 15th total of 55,600 shares. Currently,2.5% of the company's shares are short sold. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is currently 1.9 days. Currently,2.5% of the company's shares are short sold.

Coeptis Therapeutics Stock Up 2.0%

Shares of NASDAQ COEP traded up $0.27 during midday trading on Monday, hitting $13.73. 25,987 shares of the stock traded hands, compared to its average volume of 82,233. The company has a market cap of $66.18 million, a PE ratio of -2.37 and a beta of -0.59. Coeptis Therapeutics has a one year low of $2.31 and a one year high of $14.70. The business has a 50 day moving average price of $10.14 and a two-hundred day moving average price of $10.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.83 and a current ratio of 0.83.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million during the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Coeptis Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.